Presentations & Publications
Access a wide range of resources that provide detailed information on our products, programs, and collaborations.
Onalespib (AT13387) – Solid Tumors
2014
- 2014: ESMO Study of HSP90 Inhibitor AT13387 alone and combo w/ Crizotinib in the treatment of NSCLC
- 2014: ESMO Phase 1/2 of AT13387, HSP90 Inhibitor, in combo with abiraterone acetate and prednisone
- 2014 AACR: AT13387 combined with erlotinib improves response in EGFR-driven xenograft models of NSCL
- 2014 TAT: HSP90 inhibition by AT13387 can overcome & delay appearance of resistance to TKI in lung
2012
- 2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models
- 2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors
- 2012 ASCO: Phase I Study Assessing QDx2 schedule of AT13387 in Advanced Solid Tumors
- 2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model
- 2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC